Drug Approval | May 08, 2025
Lupin launches Eslicarbazepine Acetate tablets in US
Lupin is one of the first ANDA applicants and is eligible for 180 days of shared generic exclusivity
Lupin is one of the first ANDA applicants and is eligible for 180 days of shared generic exclusivity
The change of name has been carried on pursuant to the Scheme of Amalgamation
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care
IGI recently completed the dose-escalation portion of its Phase 1 clinical study in patients with heavily pretreated multiple myeloma
This outcome reflects Innoxel Lifesciences' ongoing commitment to maintaining the highest standards of quality, compliance, and regulatory excellence
Gelhaus has a proven track record of driving business growth
Topiramate is indicated as a treatment of epilepsy and migraine
The company has posted net profit of Rs. 582.01 crores for the Financial Year ended March 31, 2025
The company has posted net loss of Rs. 17.97 crores for the Financial Year ended March 31, 2025
RPG Life Sciences has reported total income of Rs. 148.15 crores during the period ended March 31, 2025
Subscribe To Our Newsletter & Stay Updated
